Medpace Holdings Inc（MEDP）財務資料MEDPMedpace Holdings Inc

Medpace Holdings, Inc. (MEDP) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Oncology, accounting for 32.1% of total sales, equivalent to $229.93M. Other significant revenue streams include Metabolic and Other. Understanding this composition is critical for investors evaluating how MEDP navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Medpace Holdings, Inc. maintains a gross margin of 30.35%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 23.12%, while the net margin is 19.20%. These profitability ratios, combined with a Return on Equity (ROE) of 117.88%, provide a clear picture of how effectively MEDP converts its operational activities into shareholder value.

In the context of the broader market, MEDP competes directly with industry leaders such as ROL and CRL. With a market capitalization of $18.49B, it holds a leading position in the sector. When comparing efficiency, MEDP's gross margin of 30.35% stands against ROL's 50.44% and CRL's 36.29%. Such benchmarking helps identify whether Medpace Holdings, Inc. is trading at a premium or discount relative to its financial performance.

Medpace has shown consistent revenue growth, with Q3 2026 revenue reaching $716 million, and a TTM revenue of $2.8 billion. The net income for Q3 2026 was $137.46 million, indicating strong profitability.